BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

ArkBio Advances Ziresovir into US Phase II Trial for Severe RSV in Infants

Shanghai Ark Biopharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II cli...

August 17, 2026 | News

China Approves Geneseeq’s PanTRKare as Companion Diagnostic for VELMARTO

NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectini...

August 14, 2026 | News

ArkBio’s Long-Acting Influenza Candidate AK0406 Secures IND Approval in China

Shanghai Ark Biopharmaceutical Co., Ltd. announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-actin...

August 14, 2026 | News

Asia-Pacific’s Geroscience Paradox: Plenty of Ageing Research, Just Five Clinical Assets

It is not a settled matter. It is a claim that has been made continuously for four years without anyone publishing the test they applied. So we wrote a tes...

August 13, 2026 | Analysis

Datasea Lists NeuroVibe Biofeedback System with US FDA as Class II 510(k)-Exempt Device

Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digit...

August 13, 2026 | News

Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializin...

August 12, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) eval...

August 11, 2026 | News

RiboX Secures FDA IND Clearance for World’s First Circular RNA-Based In Vivo CAR-T Therapy

The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy ...

August 10, 2026 | News

Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic

Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...

August 07, 2026 | News

Adneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea

Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex...

August 07, 2026 | News

Ascletis Initiates Global Phase III Trial for Oral GLP-1 Obesity Drug ASC30

-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight acr...

August 05, 2026 | News

Vaxcellbio Partners with Myellama to Advance Next-Generation NK Cell Therapy for Multiple Myeloma

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced today that it has signed a strategic Memorandum of Understanding ...

August 05, 2026 | News

MARS Bioimaging Secures First Clinical Sale of Portable Photon-Counting CT System

Christchurch-based Reform Radiology becomes inaugural clinical customer as New Zealand-developed photon-counting CT technology enters routine clinical&nb...

August 05, 2026 | News

GlycoNex Doses First Patient in Phase I Trial of Novel Glycan-Targeting ADC GNX1021

GlycoNex Inc. announced that the first patient has been successfully dosed in the First-in-Human (FIH) Phase I clinical trial of GNX1021, the Company's nov...

August 04, 2026 | News

Stay Connected